RxDoctor Payments Data

Michelle Kitson, MD

Internal Medicine · Memphis, TNNPI 1104141472

Payments from drug & device makers

$2,054in general payments, 2019–2025

Across 26 payments — averaging $79.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$836
  • Abbott$237
  • GSK$210
  • Medtronic$165
  • Gilead$162
  • Abiomed$125
  • plus $320 from 4 others

What the payments were for

  • Food & beverage$1,95895%
  • Education$975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,054 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$13,183
Medicare patients
61
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$163,516
FarxigaDapagliflozin Propanediol42$48,170
RybelsusSemaglutide30$40,125
JardianceEmpagliflozin33$36,238
Atorvastatin Calcium227$3,106
Potassium Chloride80$1,925
Rosuvastatin Calcium128$1,602
Amlodipine Besylate277$1,460
Albuterol Sulfate HfaAlbuterol Sulfate27$1,204
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$1,113
Losartan Potassium79$1,112
Allopurinol57$989
Ezetimibe29$771
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$730
Pregabalin14$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$836$203,641130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →